secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2026-10-14T11:00:31+00:00
Accession:  0001104659-26-115723
Event type: litigation
Sentiment:  positive
Materiality: 0.78
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

UT settles Liquidia patent suits: $330.4M inflow, Yutrepia PH-ILD label removal
-------------------------------------------------------------------------------

- Liquidia to pay UT $330.4M: $185M within 30 business days for past Yutrepia PH-ILD sales, plus $145.4M in two $72.7M installments due Jan 31 and Apr 30, 2027.
- UT to pay Liquidia $10M to settle the RareGen/Sandoz antitrust case; Liquidia must obtain Sandoz consent to secure dismissal.
- Liquidia must file an FDA amendment stripping the PH-ILD indication from Yutrepia's label, halt PH-ILD promotion/detailing, and end ASCENT PH-ILD trial cohorts.
- Third Circuit on Oct 7, 2026 affirmed UT on antitrust claims, reversed Sandoz's $61.6M breach-of-contract award, and revived the tortious interference claim.
- UT's '327 patent runs to Feb 3, 2042; trade-secret claims against former Liquidia executive Dr. Robert Roscigno survive the settlement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000110465926115723/0001104659-26-115723-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000110465926115723/tm2627546d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-115723

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer